The influence of lipophilicity in drug discovery and design

被引:609
作者
Arnott, John A. [1 ]
Planey, Sonia Lobo [1 ]
机构
[1] Commonwealth Med Coll, Dept Basic Sci, Scranton, PA 18509 USA
关键词
ADMET properties; compound quality; lipophilicity; physicochemical properties; PLASMA-PROTEIN BINDING; ORAL BIOAVAILABILITY; BASIC DRUGS; LOG-P; PHYSICOCHEMICAL PROPERTIES; INDUCED PHOSPHOLIPIDOSIS; MOLECULAR-PROPERTIES; DISTRIBUTION VALUES; PROPERTY PROFILES; STRUCTURAL BASIS;
D O I
10.1517/17460441.2012.714363
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The role of lipophilicity in drug discovery and design is a critical one. Lipophilicity is a key physicochemical property that plays a crucial role in determining ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties and the overall suitability of drug candidates. There is increasing evidence to suggest that control of physicochemical properties such as lipophilicity, within a defined optimal range, can improve compound quality and the likelihood of therapeutic success. Areas covered: This review focuses on understanding lipophilicity, techniques used to measure lipophilicity, and summarizes the importance of lipophilicity in drug discovery and development, including a discussion of its impact on individual ADMET parameters as well as its overall influence on the drug discovery and design process, specifically within the past 15 years. Expert opinion: A current review of the literature reveals a continued reliance on the synthesis of novel structures with increased potency, rather than a focus on maintaining optimal physicochemical properties associated with ADMET throughout drug optimization. Particular attention to the optimum region of lipophilicity, as well as monitoring of lipophilic efficiency indices, may contribute significantly to the overall quality of candidate drugs at different stages of discovery.
引用
收藏
页码:863 / 875
页数:13
相关论文
共 105 条
[1]   Structure and function of the blood-brain barrier [J].
Abbott, N. Joan ;
Patabendige, Adjanie A. K. ;
Dolman, Diana E. M. ;
Yusof, Siti R. ;
Begley, David J. .
NEUROBIOLOGY OF DISEASE, 2010, 37 (01) :13-25
[2]   PASSIVE DIFFUSION OF WEAK ORGANIC ELECTROLYTES ACROSS CACO-2 CELL MONOLAYERS - UNCOUPLING THE CONTRIBUTIONS OF HYDRODYNAMIC, TRANSCELLULAR, AND PARACELLULAR BARRIERS [J].
ADSON, A ;
BURTON, PS ;
RAUB, TJ ;
BARSUHN, CL ;
AUDUS, KL ;
HO, NFH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (10) :1197-1204
[3]   Drug-induced phospholipidosis [J].
Anderson, Nora ;
Borlak, Juergen .
FEBS LETTERS, 2006, 580 (23) :5533-5540
[4]  
[Anonymous], 1997, EUR J MED CHEM
[5]   PH-METRIC LOG-P .2. REFINEMENT OF PARTITION-COEFFICIENTS AND IONIZATION-CONSTANTS OF MULTIPROTIC SUBSTANCES [J].
AVDEEF, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1993, 82 (02) :183-190
[6]  
Azzaoui K, 2007, CHEMMEDCHEM, V2, P874, DOI 10.1002/cmdc.200700036
[7]  
Bain LJ, 1996, TOXICOL APPL PHARM, V141, P288, DOI 10.1016/S0041-008X(96)80035-4
[8]   Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure [J].
Bender, Andreas ;
Scheiber, Josef ;
Glick, Meir ;
Davies, John W. ;
Azzaoui, Kamal ;
Hamon, Jacques ;
Urban, Laszlo ;
Whitebread, Steven ;
Jenkins, Jeremy L. .
CHEMMEDCHEM, 2007, 2 (06) :861-873
[9]  
BORCHARD U, 1990, CLIN PHYSIOL BIOCH, V8, P28
[10]   Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight [J].
Camenisch, G ;
Alsenz, J ;
van de Waterbeemd, H ;
Folkers, G .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 6 (04) :313-319